Acacia Pharma Group plc Acacia Pharma To Present At The Jefferies London Healthcare Conference
10 November 2021 - 11:00PM
UK Regulatory
TIDMACPH
Cambridge, UK and Indianapolis, US -- 10 November 2021: Acacia
Pharma Group plc ("Acacia Pharma", the "Group" or the "Company")
(EURONEXT: ACPH), is pleased to announce that its Chief Executive
Officer, Mike Bolinder will present at the Jefferies London
Healthcare Conference 2021 on Tuesday, 16 November 2021.
The presentation will begin at 09:20 GMT / 10.20 CET and a live
video webcast will be available to registered conference attendees.
The link to the webcast is available
https://www.globenewswire.com/Tracker?data=PrQ5kTylH9flGytyfehdB7fNTjW-FWTaKJwuLN7x83hbF2f72dY-uhAzRg6fxBQQYXPZ5VKd8q5snedqP3hNvosblIzSs0nFCAQ2yb1f0Mk=
here.
A replay will also be available to registered attendees for 30
days post the event via the same link.
The conference will also be attended by Acacia Pharma's Chief
Financial Officer, Gary Gemignani, and Chief Medical Officer,
Gabriel Fox and alongside the presentation the Company will be
conducting a series of 1x1 meetings with investors.
Presentation slides will be made available through the investor
section of the Company's website following the presentation.
Contacts
Acacia Pharma Group plc International Media
Mike Bolinder, CEO Mark Swallow, Frazer Hall, David
Gary Gemignani, CFO Dible
+44 1223 919760 / +1 317 505 1280 MEDiSTRAVA Consulting
mailto:IR@acaciapharma.com IR@acaciapharma.com +44 20 7638 9571
mailto:acaciapharma@medistrava.com
acaciapharma@medistrava.com
----------------------------------------------- ------------------------------------
US Investors Media in Belgium and the Netherlands
LifeSci Advisors Chris Van Raemdonck
Irina Koffler +32 499 58 55 31
+1 917-734-7387 mailto:chrisvanraemdonck@telenet.be
mailto:ikoffler@lifesciadvisors.com chrisvanraemdonck@telenet.be
ikoffler@lifesciadvisors.com
----------------------------------------------- ------------------------------------
About Acacia Pharma
Acacia Pharma is a hospital pharmaceutical company focused on
the development and commercialization of new products aimed at
improving the care of patients undergoing significant treatments
such as surgery, other invasive procedures, or cancer chemotherapy.
The Company has identified important and commercially attractive
unmet needs in these areas that its product portfolio aims to
address.
Barhemsys(R) (amisulpride) injection is a selective dopamine
(D(2) and D(3) ) receptor antagonist approved and available in the
US for the treatment and prevention of postoperative nausea &
vomiting (PONV) in adult patients.
Please see full prescribing information, including Important
Safety Information, at
https://www.globenewswire.com/Tracker?data=RaBY3sd3IJFqQo4PueEb8a0fvh8cLLY1EVDougO_O98pmIExINLPIWyXP6KITnkcxMlCaBvDCfKA6-leNkc3hA==
www.BARHEMSYS.com.
Byfavo(R) (remimazolam) for injection, is an IV benzodiazepine
sedative approved and available in the US for the induction and
maintenance of procedural sedation in adults undergoing procedures
lasting 30 minutes or less. Byfavo is in-licensed from Paion UK
Limited for the US market.
Please see full prescribing information, including Important
Safety Information and Boxed Warning, at
https://www.globenewswire.com/Tracker?data=RaBY3sd3IJFqQo4PueEb8VI3arnSwTCzmsD9u5YjArA7eN1qoCJDc536FPCqBODFVWoKesaPrKaej31D5QlF4g==
www.BYFAVO.com.
APD403 (intravenous and oral amisulpride), a selective dopamine
antagonist for chemotherapy induced nausea & vomiting (CINV)
has successfully completed one proof-of-concept and one Phase 2
dose-ranging study in patients receiving highly emetogenic
chemotherapy.
Acacia Pharma has its US headquarters in Indianapolis, IN and
its R&D operations are centred in Cambridge, UK. The Company is
listed on the Euronext Brussels exchange under the ISIN code
GB00BYWF9Y76 and ticker symbol ACPH.
This release is intended for investors and media only.
https://www.globenewswire.com/Tracker?data=RaBY3sd3IJFqQo4PueEb8dbC9rredi7m5zLGwKvyFJJoFwSwtQCG0jsvvY8SyVuQ0LTR-aYE-fDQXAzETnx_1ewThO8r5B69uEFPGykNgjQ=
www.acaciapharma.com
Forward looking statements
This announcement includes forward-looking statements, which are
based on current expectations and projections about future events.
These statements may include, without limitation, any statements
preceded by, followed by or including words such as "believe",
"expect", "intend", "may", "plan", "will", "should", "could" and
other words and terms of similar meaning or the negative thereof.
Forward-looking statements may and often do differ materially from
actual results. These forward-looking statements are subject to
risks, uncertainties and assumptions about the Company and its
subsidiaries and investments, including, among other things, the
development of its business, trends in its operating industry, and
future capital expenditures and acquisitions. By their nature,
forward-looking statements involve risk and uncertainty because
they relate to future events and circumstances. Any forward-looking
statements reflect the Company's current view with respect to
future events and are subject to risks relating to future events
and other risks, uncertainties and assumptions relating to the
Group's business, results of operations, financial position,
prospects, growth or strategies and the industry in which it
operates. Save as required by law or applicable regulation, the
Company and its affiliates expressly disclaim any obligation or
undertaking to update, review or revise any forward-looking
statement contained in this announcement whether as a result of new
information, future developments or otherwise. Forward-looking
statements speak only as of the date they are made.
(END) Dow Jones Newswires
November 10, 2021 07:00 ET (12:00 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Acacia Pharma (LSE:0PNT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acacia Pharma (LSE:0PNT)
Historical Stock Chart
From Apr 2023 to Apr 2024
